Research Summary:
α-(-)-bisabolol, a natural monocyclic sesquiterpene found in essential oils, has garnered significant interest in the chemical and pharmaceutical industries and is currently utilized in various formulations, particularly in cosmetics. This study aimed to evaluate its therapeutic potential against skin inflammation using in-vitro, in-vivo, and in-silico assays.
Lipopolysaccharide (LPS) and 12-O-tetradecanoyl-phorbol-13-acetate (TPA)-induced production of pro-inflammatory cytokines (TNF-α and IL-6) in macrophage cells, as well as TPA-induced skin inflammation in mice, were significantly inhibited by α-(-)-bisabolol. Furthermore, TPA-induced ear thickness, ear weight, lipid peroxidation, and histopathological damage in ear tissue were also significantly reduced by the topical application of α-(-)-bisabolol in a dose-dependent manner.
In-vitro and in-vivo toxicity profiles suggest that α-(-)-bisabolol is safe for topical application on the skin. The molecular docking study revealed a strong binding affinity of α-(-)-bisabolol to the active site of pro-inflammatory proteins. These findings suggest that α-(-)-bisabolol could be a promising therapeutic candidate for the treatment of skin inflammation.
Keywords: α-(-)-bisabolol, anti-inflammatory, macrophage, 12-O-tetradecanoylphorbol-13-acetate, mice, LPS.
<Access the full report below>